VIPR2 and type 2 diabetes mellitus: CTS-SeNPs conjugated with a novel peptide, consisting of a recombinant pituitary adenylate cyclase-activating polypeptide (PACAP)-derived peptide DBAYL capable of specifically activating the vasoactive intestinal peptide receptor 2, also known as the VPAC2 receptor, that influences glucose-dependent insulin secretion, enhances insulin sensitivity, hyperglycemia, and lipid profiles, thus demonstrating the potential of this assembly to become a long-acting anti-T2D therapeutic [573].